clinical trial · NCT02479204
Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441
Viatris Innovation GmbH·phase1·terminated·n = 10
Healthy SubjectsACT-334441 2 mgACT-334441 4 mgPlaceboAtenololDiltiazem ER
brief summary
The aim of the study is to investigate the safety of the concomitant administration of ACT-334441 with cardiovascular drugs.
started
Apr 28, 2015
primary completion
May 1, 2016
completion
May 1, 2016
last updated
Sep 22, 2025
detailed description
The study will consist of two parts: a pilot part (Part A) that will be completed prior to the start of the main part (Part B). The Subjects who will participate in Part A are excluded from Part B.
official title
Single-center, Open-label, Randomized, Multiple-dose, Parallel-group Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441 Combined With Calcium-channel Blocker (Diltiazem) or Beta-blocker (Atenolol) Treatment in Healthy Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol